#1 Clinical Trials Search in Europe

Study Comparing Amoxicillin and Amoxicillin/Clavulanic Acid for Treating Community-Acquired Pneumonia in Patients Aged 65 and Older

3 1 1 1

What is this study about?

This clinical trial is focused on studying the treatment of community-acquired pneumonia in patients who are 65 years or older and are hospitalized in a regular hospital ward, not in intensive care. The study compares two treatments: one using amoxicillin alone and the other using a combination of amoxicillin and clavulanic acid. These medications are commonly used antibiotics, with amoxicillin being a narrow-spectrum antibiotic, meaning it targets specific types of bacteria, and the combination with clavulanic acid being a broad-spectrum antibiotic, which targets a wider range of bacteria.

The purpose of the study is to determine if the treatment with amoxicillin alone is as effective as the combination treatment in terms of clinical success. Clinical success is defined as the patient surviving after completing the antibiotic treatment, with the resolution of symptoms such as cough, difficulty breathing, and chest pain, and no new symptoms or complications related to the pneumonia. The study will follow patients for 30 days after they are admitted to the hospital to assess the effectiveness of the treatments.

Participants in the study will receive either the amoxicillin alone or the combination of amoxicillin and clavulanic acid for a maximum of five days. The study will monitor various outcomes, including the improvement of symptoms, the need for additional antibiotics, and overall survival. The study aims to provide valuable information on the best treatment approach for older adults with community-acquired pneumonia who are hospitalized in non-intensive care settings.

1 joining the study

Upon joining the study, you will be required to provide written informed consent. If you are unable to write, a trusted person can provide consent on your behalf.

You must be 65 years or older, hospitalized for community-acquired pneumonia, and able to understand oral and written French.

2 initial assessment

An initial assessment will be conducted to confirm your eligibility. This includes checking for symptoms like cough, sputum production, difficulty breathing, or chest pain, and reviewing your medical history.

A chest X-ray or similar imaging will be performed to confirm pneumonia.

3 randomization and treatment

You will be randomly assigned to receive either amoxicillin or amoxicillin/clavulanate.

If assigned to amoxicillin, you will receive 1 g intravenously or 500 mg orally, depending on your condition.

If assigned to amoxicillin/clavulanate, you will receive 1 g/200 mg intravenously or 500 mg/62.5 mg orally.

The treatment will continue as prescribed by the medical team, typically for the duration of your hospital stay.

4 monitoring and follow-up

Your health will be monitored throughout the treatment. This includes regular checks of your symptoms and any side effects.

You will be contacted by phone or in person to assess your progress and any changes in your condition.

5 completion and evaluation

At the end of the treatment, your symptoms will be evaluated to determine the success of the therapy.

A follow-up will occur 30 days after hospital admission to assess your recovery and any need for further treatment.

Who Can Join the Study?

  • Patient must be 65 years or older.
  • Patient can have other long-term health conditions, but must have a normal immune system.
  • Patient must be admitted to the hospital for community-acquired pneumonia (CAP), which is a lung infection.
  • Patient must show at least two signs of pneumonia, such as:
    • Cough
    • Producing mucus (sputum)
    • Difficulty breathing (dyspnea)
    • Fast breathing (tachypnea)
    • Chest pain when breathing (pleuritic pain)
    • Unusual lung sounds when a doctor listens with a stethoscope
    • Fever (temperature over 38°C) or low body temperature (below 36°C)
  • Patient must have a chest X-ray or scan showing a new lung infection.
  • Patient must give written consent to participate in the study. If unable to write, a trusted person can give consent for them.
  • Patient must understand both spoken and written French.
  • Patient must be able to make or receive phone calls, or have a relative who can help with phone communication, especially with the medical team.

Who Cannot Join the Study?

  • Patients who are younger than 65 years old.
  • Patients who are not hospitalized in a non-ICU ward. An ICU is an Intensive Care Unit, which is a special department in a hospital for very sick patients.
  • Patients who do not have community-acquired pneumonia. This is a type of lung infection that you get outside of a hospital.
  • Patients who are not being treated with either narrow-spectrum or broad-spectrum antimicrobial therapy. Narrow-spectrum therapy targets specific types of bacteria, while broad-spectrum therapy targets a wider range of bacteria.
  • Patients who are part of a vulnerable population. This means groups of people who might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Centre Hospitalier Regional Et Universitaire De Brest Brest France
Oncopole Claudius Regaud Toulouse France
CHU Grenoble Alpes La Tronche France

Other Sites

Site Name City Country Status
Centre Hospitalier Bretagne Atlantique Vannes France
Centre Hospitalier De Perigueux Perigueux France
Hôpital Avicenne Bobigny France
Centre Hospitalier Universitaire De Nantes Nantes France
Hopital Purpan Toulouse France
Centre Hospitalier Saint Nazaire St Nazaire France
Apkuvcvaih Pntyfegz Hqpeylpa Da Mppobvlws Marseille France
Cwcyjc Hzugcqiwptg Rybjndzg Dahxprfqfvibou Angers France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Recruiting
01.03.2024

Trial locations

Investigated drugs:

Amoxicillin is an antibiotic used to treat infections caused by bacteria. In this trial, it is being used to treat community-acquired pneumonia in patients who are 65 years or older and are hospitalized in a regular hospital ward, not in intensive care. The goal is to see if this medication is effective enough on its own to treat the infection.

Amoxicillin/Clavulanate is a combination of two medications. Amoxicillin is an antibiotic that fights bacteria, and clavulanate is a substance that helps prevent certain bacteria from becoming resistant to amoxicillin. This combination is used in the trial to treat community-acquired pneumonia in older patients, and the study aims to compare its effectiveness to amoxicillin alone.

Investigated diseases:

Community-Acquired Pneumonia – Community-acquired pneumonia is an infection of the lungs acquired outside of a hospital setting. It typically begins when bacteria, viruses, or fungi enter the lungs and cause inflammation. The disease progresses with symptoms such as cough, fever, chills, and difficulty breathing. As the infection advances, patients may experience chest pain, fatigue, and production of phlegm. In severe cases, the infection can spread to the bloodstream or other parts of the body. The progression and severity of symptoms can vary based on the individual’s age, overall health, and the specific pathogen causing the infection.

Trial ID:
2023-503645-63-00
Protocol code:
RC20_0015
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on High-Dose Short-Course Antibiotics for Critically Ill Patients with Pneumonia, Intra-Abdominal, or Bloodstream Infections: Ceftriaxone, Linezolid, and Cefotaxime

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium The Netherlands

  • Study on the Effect of Amoxicillin in Preschool Children with Pneumonia

    Recruiting

    3 1 1
    Investigated drugs:
    Norway